AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca total projects in clinical development pipeline (count)
Clinical Trials Appendix (Quarterly & Annual Pipeline at a Glance)
Latest, FY2025
197
Period ended Dec 31, 2025
Change on a year earlier
+3.1%
191 in FY2024
History
3 years
Since FY2023
Sources
3
Documents cited below
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Total projects in clinical development pipeline (count) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 197 | +3.1% | Clinical Trials Appendix (2025Q4) ↗ |
| FY2024 | Dec 31, 2024 | 191 | +7.3% | Clinical Trials Appendix (2024Q4) ↗ |
| FY2023 | Dec 31, 2023 | 178 | – | Clinical Trials Appendix (2023Q4) ↗ |
Breakdown
What makes up total projects in clinical development pipeline (count)
Cite this data
StockData. (2026). AstraZeneca Total projects in clinical development pipeline (count), annual FY2023–FY2025 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/cta_total_projects
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.